Last edition
News about Biotechnology
Currently, the prevalent approach is to contain the spread of the virus by reducing interpersonal contacts and vaccination. An alternative strategy could involve the understanding of the molecular mechanisms underlying the known risk factors and to correct them, when possible, as a prevention/treatment of the disease
Biotechnology | 24/06/2021 | By Darshana | 228
Can-Fite BioPharma announced the Chinese National Intellectual Property Administration has issued a Notice of Allowance for its patent titled An A3 Adenosine Receptor Ligand for use in Treating Ectopic Fat Accumulation. This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fite's drug platform technology
Biotechnology | 20/06/2021 | By Darshana | 122
Researchers to have access to Cryo-EM facilities to combat new and emerging diseases
The Department of Science and Technology (DST) has announced that the researchers in the country would soon have access to four Cryogenic-Electron Microscopy (Cryo-EM) facilities paving the way towards establishment of leadership in structural biology, enzymology, and drug discovery to combat new and emerging diseases
Biotechnology | 18/06/2021 | By Darshana | 136
Debiopharm, a Swiss-based global biopharmaceutical company, and Ubix Therapeutics, a South Korea-based biotech company, announced their co-research agreement combining two novel proprietary technologies to specifically target cancer cells
Biotechnology | 17/06/2021 | By Darshana | 330
Zydus Cadila gets US FDA tentative marketing nod for epilepsy drug, brivaracetam
Zydus Cadila has received tentative approval from the US FDA to market brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. Brivaracetam is used to treat partial-onset of seizures (epilepsy).
Biotechnology | 14/06/2021 | By Darshana | 145
Roche gets CE mark for SARS-CoV-2 Antigen Self Test Nasal for at-home testing
Roche announced it has received CE mark for its SARS-CoV-2 Antigen Self Test Nasal for at-home testing. The test will be available in countries accepting the CE mark through pharmacies and other locations, in packs of five tests
Biotechnology | 09/06/2021 | By Darshana | 136
Lupin receives US FDA approval for generic Truvada tablets
Global pharma major Lupin Limited has received approval for its emtricitabine and tenofovir disoproxil fumarate tablets, 200 mg/300 mg, from the United States Food and Drug Administration (FDA), to market a generic equivalent of Truvada tablets, 200 mg/300 mg, of Gilead Sciences, Inc.
Biotechnology | 07/06/2021 | By Darshana | 110
Moderna inks agreement with Government of the Republic of Botswana for supply of Covid-19 vaccine
Moderna announced a supply agreement with the Government of the Republic of Botswana for Moderna's vaccine against Covid-19, to support the government's ongoing efforts to secure access to Covid-19 vaccines for the people of Botswana. The Company also announced that the Botswana Medicines Regulatory Authority (BMRA)
Biotechnology | 06/06/2021 | By Darshana | 131
Glenmark Pharma receives US FDA approval for theophylline ER tablets
Glenmark Pharmaceuticals Limited (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for theophylline extended release tablets, 300 mg and 450 mg, bioequivalent and therapeutically equivalent to the reference listed drug, theophylline extended release tablets, 300 mg and 450 mg, of Alembic Pharmaceuticals Lmt
Biotechnology | 04/06/2021 | By Darshana | 123
Glenmark Pharma launches generic Banzel tablets
Glenmark Pharmaceuticals has launched rufinamide tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for rufinamide tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval
Biotechnology | 01/06/2021 | By Darshana | 148
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy